Eric Venker, the President & Immunovant CEO of $ROIV, sold 683,818 shares of the company on 09-19-2025 for an estimated $10,223,079. We received data on the trade from a recent SEC filing. This was a sale of approximately 25.8% of their shares of this class of stock. Following this trade, they now own 1,969,767 shares of this class of $ROIV stock.
$ROIV Insider Trading Activity
$ROIV insiders have traded $ROIV stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:
- VIVEK RAMASWAMY has made 0 purchases and 9 sales selling 4,565,211 shares for an estimated $54,125,623.
- ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 11 sales selling 3,211,000 shares for an estimated $42,265,718.
- MATTHEW GLINE (CEO) purchased 3,315 shares for an estimated $49,957
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ROIV Hedge Fund Activity
We have seen 175 institutional investors add shares of $ROIV stock to their portfolio, and 186 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- QVT FINANCIAL LP removed 36,412,144 shares (-55.3%) from their portfolio in Q2 2025, for an estimated $410,364,862
- VIKING GLOBAL INVESTORS LP removed 11,775,973 shares (-25.6%) from their portfolio in Q2 2025, for an estimated $132,715,215
- MORGAN STANLEY added 8,767,207 shares (+24.4%) to their portfolio in Q2 2025, for an estimated $98,806,422
- INVESCO LTD. removed 8,196,427 shares (-83.0%) from their portfolio in Q2 2025, for an estimated $92,373,732
- DIMENSIONAL FUND ADVISORS LP added 5,297,818 shares (+204.7%) to their portfolio in Q2 2025, for an estimated $59,706,408
- TOMS CAPITAL INVESTMENT MANAGEMENT LP removed 4,095,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $46,150,650
- FMR LLC added 3,842,770 shares (+7.4%) to their portfolio in Q2 2025, for an estimated $43,308,017
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ROIV Congressional Stock Trading
Members of Congress have traded $ROIV stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ROIV Analyst Ratings
Wall Street analysts have issued reports on $ROIV in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 09/18/2025
- Guggenheim issued a "Buy" rating on 09/18/2025
- Jefferies issued a "Buy" rating on 09/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/18/2025
- Goldman Sachs issued a "Buy" rating on 09/18/2025
- Leerink Partners issued a "Outperform" rating on 09/18/2025
- Citigroup issued a "Buy" rating on 09/02/2025
To track analyst ratings and price targets for $ROIV, check out Quiver Quantitative's $ROIV forecast page.
$ROIV Price Targets
Multiple analysts have issued price targets for $ROIV recently. We have seen 8 analysts offer price targets for $ROIV in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Brian Cheng from JP Morgan set a target price of $20.0 on 09/18/2025
- Yatin Suneja from Guggenheim set a target price of $21.0 on 09/18/2025
- David Risinger from Leerink Partners set a target price of $22.0 on 09/18/2025
- Dennis Ding from Jefferies set a target price of $20.0 on 09/18/2025
- Corinne Jenkins from Goldman Sachs set a target price of $24.0 on 09/18/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $20.0 on 09/18/2025
- Chi Fong from B of A Securities set a target price of $16.5 on 09/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
